Skip to main content
Premium Trial:

Request an Annual Quote

Genetic Technologies Says Core US Patent Claims Upheld

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Genetic Technologies today said that the US Patent and Trademark Office has upheld, without amendment, the firm's core US patent covering non-coding DNA.

The Australian firm's patent, US No. 5,612,179, was challenged last year and a re-examination was launched in June.

"This is the best possible result for the company," Genetic Technologies CEO Paul MacLeman said in a statement. "We were not expecting to hear back from the USPTO so soon. The USPTO's blanket rejection of all of the arguments put forward by our challengers reinforces the strength of the patent."

The patent is at the center of a lawsuit filed by Genetic Technologies against several defendants earlier this year. Last week, the firm said that it had settled with one of the defendants, Gen-Probe, which took a license to the non-coding patents.

MacLeman said that the timing of the USPTO's decision is ideal, considering the firm's "new US Assertion Program." He added, "All of the claims of the '179 will now be available for assertion against those parties employing the technology."

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.